ALBIREO PHARMA INC's ticker is ALBO and the CUSIP is 01345P106. A total of 111 filers reported holding ALBIREO PHARMA INC in Q1 2022. The put-call ratio across all filers is 0.05 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $522,962 | -65.4% | 24,200 | -69.0% | 0.00% | -66.7% |
| Q3 2022 | $1,512,000 | -70.1% | 78,100 | -54.0% | 0.01% | -70.0% |
| Q1 2022 | $5,059,000 | +344.2% | 169,600 | +246.9% | 0.02% | +300.0% |
| Q4 2021 | $1,139,000 | -75.4% | 48,890 | -72.1% | 0.01% | -83.3% |
| Q2 2020 | $4,636,000 | -45.0% | 175,000 | -66.0% | 0.03% | -55.9% |
| Q1 2020 | $8,431,000 | +56.4% | 515,000 | +142.9% | 0.07% | +142.9% |
| Q4 2019 | $5,390,000 | +206.6% | 212,030 | +141.2% | 0.03% | +154.5% |
| Q3 2019 | $1,758,000 | -67.3% | 87,906 | -47.4% | 0.01% | -60.7% |
| Q2 2019 | $5,383,000 | -8.9% | 166,964 | -9.0% | 0.03% | +3.7% |
| Q1 2019 | $5,910,000 | +1658.9% | 183,495 | +1239.4% | 0.03% | +1250.0% |
| Q4 2018 | $336,000 | -91.4% | 13,700 | -92.7% | 0.00% | -88.2% |
| Q3 2017 | $3,910,000 | +1121.9% | 186,640 | +1100.9% | 0.02% | +750.0% |
| Q2 2017 | $320,000 | – | 15,542 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 514,082 | $11,973,000 | 7.17% |
| Privium Fund Management B.V. | 379,117 | $8,959,000 | 1.78% |
| Birchview Capital, LP | 113,000 | $2,632,000 | 1.70% |
| Sio Capital Management, LLC | 213,913 | $4,982,000 | 1.50% |
| Perceptive Advisors | 4,720,278 | $109,936,000 | 0.85% |
| Chicago Capital, LLC | 849,239 | $19,779,000 | 0.74% |
| APOGEM CAPITAL LLC | 38,601 | $899,000 | 0.59% |
| Samsara BioCapital, LLC | 100,000 | $2,329,000 | 0.45% |
| Artal Group S.A. | 600,000 | $13,974,000 | 0.38% |
| RICE HALL JAMES & ASSOCIATES, LLC | 458,011 | $10,667,000 | 0.38% |